Literature DB >> 24275699

Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders.

George Foussias1, Ofer Agid2, Gagan Fervaha3, Gary Remington3.   

Abstract

Negative symptoms have long been recognized as a central feature of the phenomenology of schizophrenia, dating back to the early descriptions by Kraepelin and Bleuler. Over the ensuing century, there have been important clarifications and reconceptualizations regarding the phenomenology of negative symptoms in schizophrenia. This review explores these developments, including the delineation of two underlying subdomains of negative symptoms - amotivation (i.e., avolition/apathy and asociality) and diminished expression (i.e., poverty of speech and affective flattening). Further, advances in our understanding of specific motivational and hedonic deficits seen in schizophrenia are explored. The findings that negative symptoms stand apart from depressive and cognitive symptoms in schizophrenia are also discussed. In terms of the predictors of functional outcomes in schizophrenia, we explore both the direct role of negative symptoms in this regard, as well as their indirect role through cognition. We then broaden our examination of negative symptoms to related disorders across the schizophrenia spectrum, as well as to other neuropsychiatric illnesses, where negative symptoms have been increasingly recognized. We explore the differential characteristics of negative symptoms across these illnesses, and their relevance to functional outcomes. This transdiagnostic presence and relevance of negative symptoms highlights the need for continued exploration of their phenomenology and neurobiology as we move to develop effective interventions to address these debilitating symptoms and improve functional outcomes.
© 2013 Published by Elsevier B.V. and ECNP.

Entities:  

Keywords:  Anhedonia; Cognition; Diminished expression; Motivation; Negative symptoms; Outcomes

Mesh:

Year:  2013        PMID: 24275699     DOI: 10.1016/j.euroneuro.2013.10.017

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  51 in total

1.  Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.

Authors:  Samantha E Yohn; Daniela Alberati; Merce Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2017-01-12       Impact factor: 4.530

Review 2.  A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis.

Authors:  Gregory P Strauss; Andrea Pelletier-Baldelli; Katherine Frost Visser; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Res       Date:  2020-06-07       Impact factor: 4.939

3.  Factor Analysis of Negative Symptom Items in the Structured Interview for Prodromal Syndromes.

Authors:  Matilda Azis; Gregory P Strauss; Elaine Walker; William Revelle; Richard Zinbarg; Vijay Mittal
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

4.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

5.  Initial development and preliminary psychometric properties of the Prodromal Inventory of Negative Symptoms (PINS).

Authors:  Andrea Pelletier-Baldelli; Gregory P Strauss; Katherine H Visser; Vijay A Mittal
Journal:  Schizophr Res       Date:  2017-02-08       Impact factor: 4.939

6.  Dynamic endophenotypes and longitudinal trajectories: capturing changing aspects of development in early psychosis.

Authors:  Jai L Shah; M Mallar Chakravarty; Ridha Joober; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2016-04       Impact factor: 6.186

Review 7.  Crossing the Worm-Brain Barrier by Using Caenorhabditis elegans to Explore Fundamentals of Human Psychiatric Illness.

Authors:  Donard S Dwyer
Journal:  Mol Neuropsychiatry       Date:  2018-01-11

8.  Insulin Signaling Deficiency Produces Immobility in Caenorhabditis elegans That Models Diminished Motivation States in Man and Responds to Antidepressants.

Authors:  Julie Dagenhardt; Angeline Trinh; Halen Sumner; Jeffrey Scott; Eric Aamodt; Donard S Dwyer
Journal:  Mol Neuropsychiatry       Date:  2017-09-21

9.  Deconstructing Negative Symptoms in Individuals at Clinical High-Risk for Psychosis: Evidence for Volitional and Diminished Emotionality Subgroups That Predict Clinical Presentation and Functional Outcome.

Authors:  Tina Gupta; Henry R Cowan; Gregory P Strauss; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

10.  Age-Dependent Specific Changes in Area CA2 of the Hippocampus and Social Memory Deficit in a Mouse Model of the 22q11.2 Deletion Syndrome.

Authors:  Rebecca A Piskorowski; Kaoutsar Nasrallah; Anastasia Diamantopoulou; Jun Mukai; Sami I Hassan; Steven A Siegelbaum; Joseph A Gogos; Vivien Chevaleyre
Journal:  Neuron       Date:  2016-01-06       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.